投资工具 / 美股
Quest Diagnostics · DGX
数据仅供参考,不构成投资建议。
投资工具 / 美股
数据仅供参考,不构成投资建议。
| 季度 | 截止日 | 申报日 | 营收 | 营收同比 g | Δg | 推导方式 |
|---|---|---|---|---|---|---|
| 2026Q3 | 2026-09-30 | 2026-10-23 | $3.1B | +10.0% | −0.2pp | 3M |
| 2026Q2 | 2026-06-30 | 2026-07-23 | $3.04B | +10.2% | +1.1pp | 3M |
| 2026Q1 | 2026-03-31 | 2026-04-22 | $2.9B | +9.2% | +2.1pp | 3M |
| 2025Q4 | 2025-12-31 | 2026-10-23 | $2.81B | +7.1% | −6.1pp | FY-9M |
| 2025Q3 | 2025-09-30 | 2026-10-23 | $2.82B | +13.2% | −2.0pp | 3M |
| 2025Q2 | 2025-06-30 | 2026-07-23 | $2.76B | +15.2% | +3.1pp | 3M |
| 2025Q1 | 2025-03-31 | 2026-04-22 | $2.65B | +12.1% | −2.5pp | 3M |
| 2024Q4 | 2024-12-31 | 2026-02-26 | $2.62B | +14.6% | +6.1pp | FY-9M |
口径:单季同比;Δg = 本季 g − 上季 g;按财季映射日历季度;申报日可见。† 不连续点(上年同季营收 ≤0 或 Δg 幅度超过 50pp)。 · 数据截至 2026-11-16 · 来源 SEC EDGAR XBRL
| 季度 | 截止日 | 毛利 | 销货成本 | 毛利率 | 环比 | 同比 | Δ² |
|---|---|---|---|---|---|---|---|
| 2026Q3 | 2026-09-30 | 缺口径:GrossProfit 最后申报于 2020-12-31 | $2.06B | 33.6% | −10bp | −5bp | +35bp |
| 2026Q2 | 2026-06-30 | 缺口径:GrossProfit 最后申报于 2020-12-31 | $2.02B | 33.7% | +121bp | −40bp |
| 季度 | 截止日 | 合同负债 | CL g | RPO | RPO g | 账单额 | 账单额 g | RPO 覆盖 |
|---|---|---|---|---|---|---|---|---|
| 2026Q3 | 2026-09-30 | 无数据 | 无数据 | 无数据 | 无数据 | 无数据 | 无数据 | 无数据 |
| 2026Q2 | 2026-06-30 | 无数据 | 无数据 |
| 季度 | 截止日 | OCF TTM | OCF g | CapEx TTM | CapEx g | FCF TTM | CapEx 密度 | SBC/FCF | SBC/Rev |
|---|---|---|---|---|---|---|---|---|---|
| 2026Q3 | 2026-09-30 | $1.95B | +3.5% | $576M | +17.1% | $1.38B | 4.9% | 6.4% | 0.7% |
| 2026Q2 | 2026-06-30 | $1.9B |
| 交易日 | 申报日 | 申报人 | 头衔 | 代码 | 股数 | 价格 | 金额 | 10b5-1 |
|---|---|---|---|---|---|---|---|---|
| 2026-11-13 | 2026-11-16 | Deppe Michael J | SVP, Corp. Controller & CAO | S | 5,515 | $260.17 | $1.43M |
口径:修正广度 =(近 30 日上调 − 下调)/(上调 + 下调),样本 < 3 不出;只展示衍生指标,不展示一致预期原值。 · 数据截至 2026-11-16 · 来源:Yahoo Finance / Nasdaq
未覆盖(期权覆盖为 S&P 500 期权持仓前 100 名每日、其余每周轮换)
口径:本股的警报事件历史(含基线);事件保留 90 天。
该类型不适用:存货
| −40bp |
| 2026Q1 | 2026-03-31 | 缺口径:GrossProfit 最后申报于 2020-12-31 | $1.95B | 32.5% | +11bp | −0bp | +30bp |
| 2025Q4 | 2025-12-31 | 缺口径:GrossProfit 最后申报于 2020-12-31 | $1.9B | 32.4% | −127bp | −31bp | −141bp |
| 2025Q3 | 2025-09-30 | 缺口径:GrossProfit 最后申报于 2020-12-31 | $1.87B | 33.7% | −45bp | +110bp | +49bp |
| 2025Q2 | 2025-06-30 | 缺口径:GrossProfit 最后申报于 2020-12-31 | $1.82B | 34.2% | +161bp | +61bp | +66bp |
| 2025Q1 | 2025-03-31 | 缺口径:GrossProfit 最后申报于 2020-12-31 | $1.79B | 32.5% | −19bp | −5bp | −61bp |
| 2024Q4 | 2024-12-31 | 缺口径:GrossProfit 最后申报于 2020-12-31 | $1.76B | 32.7% | +14bp | +57bp | +83bp |
缺口径:毛利(GrossProfit 最后申报于 2020-12-31)
口径:GM = 毛利/营收;毛利缺失时用 营收−销货成本 推导;环比/同比为基点。 · 数据截至 2026-11-16 · 来源 SEC EDGAR XBRL
| 无数据 |
| 无数据 |
| 无数据 |
| 无数据 |
| 2026Q1 | 2026-03-31 | 无数据 | 无数据 | 无数据 | 无数据 | 无数据 | 无数据 | 无数据 |
| 2025Q4 | 2025-12-31 | 无数据 | 无数据 | 无数据 | 无数据 | 无数据 | 无数据 | 无数据 |
| 2025Q3 | 2025-09-30 | 无数据 | 无数据 | 无数据 | 无数据 | 无数据 | 无数据 | 无数据 |
| 2025Q2 | 2025-06-30 | 无数据 | 无数据 | 无数据 | 无数据 | 无数据 | 无数据 | 无数据 |
| 2025Q1 | 2025-03-31 | 无数据 | 无数据 | 无数据 | 无数据 | 无数据 | 无数据 | 无数据 |
| 2024Q4 | 2024-12-31 | 无数据 | 无数据 | 无数据 | 无数据 | 无数据 | 无数据 | 无数据 |
口径:g = 同比;账单额 = 营收 + Δ合同负债(同口径);RPO 覆盖 = RPO / TTM 营收。跨口径(总额/仅流动)不比较。 合同负债口径: — · 数据截至 2026-11-16 · 来源 SEC EDGAR XBRL
| +13.4% |
| $554M |
| +22.0% |
| $1.35B |
| 4.8% |
| 6.5% |
| 0.8% |
| 2026Q1 | 2026-03-31 | $1.85B | +23.8% | $524M | +19.6% | $1.33B | 4.6% | 6.5% | 0.8% |
| 2025Q4 | 2025-12-31 | $1.89B | +41.4% | $527M | +24.0% | $1.36B | 4.8% | 6.5% | 0.8% |
| 2025Q3 | 2025-09-30 | $1.89B | +34.9% | $492M | +31.6% | $1.39B | 4.5% | 6.5% | 0.8% |
| 2025Q2 | 2025-06-30 | $1.68B | +34.5% | $454M | +21.7% | $1.22B | 4.3% | 7.3% | 0.8% |
| 2025Q1 | 2025-03-31 | $1.49B | +12.2% | $438M | +13.8% | $1.06B | 4.3% | 8.3% | 0.9% |
| 2024Q4 | 2024-12-31 | $1.33B | +4.9% | $425M | +4.2% | $909M | 4.3% | 9.7% | 0.9% |
口径:TTM = 近四个离散单季之和;FCF = OCF − CapEx;CapEx 密度 = CapEx/营收 TTM;FCF≤0 时 SBC/FCF 不计算。 · 数据截至 2026-11-16 · 来源 SEC EDGAR XBRL
| ✓ |
| 2026-11-13 | 2026-11-16 | Deppe Michael J | SVP, Corp. Controller & CAO | S | 6,261 | $260.17 | $1.63M | ✓ |
| 2026-11-09 | 2026-11-12 | Plewman Patrick | SVP for Diagnostic Services | S | 650 | $257.34 | $167.27K | ✓ |
| 2026-11-09 | 2026-11-12 | Plewman Patrick | SVP for Diagnostic Services | S | 6,793 | $257.34 | $1.75M | ✓ |
| 2026-11-09 | 2026-11-12 | Plewman Patrick | SVP for Diagnostic Services | S | 4,274 | $257.34 | $1.1M | ✓ |
| 2026-11-03 | 2026-11-05 | Doherty Catherine T. | Executive Vice President | S | 2,907 | $251.24 | $730.35K | ✓ |
| 2026-11-03 | 2026-11-05 | Doherty Catherine T. | Executive Vice President | S | 2,877 | $250.49 | $720.65K | ✓ |
| 2026-11-03 | 2026-11-05 | Doherty Catherine T. | Executive Vice President | S | 3,004 | $249.40 | $749.21K | ✓ |
| 2026-11-03 | 2026-11-05 | Doherty Catherine T. | Executive Vice President | S | 2,358 | $248.38 | $585.69K | ✓ |
| 2026-11-03 | 2026-11-05 | Doherty Catherine T. | Executive Vice President | S | 1,151 | $246.98 | $284.28K | ✓ |
| 2026-11-03 | 2026-11-05 | Doherty Catherine T. | Executive Vice President | S | 5,990 | $246.26 | $1.48M | ✓ |
| 2026-11-03 | 2026-11-05 | Doherty Catherine T. | Executive Vice President | S | 3,818 | $245.45 | $937.14K | ✓ |
| 2026-10-26 | 2026-10-28 | PFEIFFER GARY M | — | S | 1,203 | $243.00 | $292.33K | ✓ |
| 2026-09-01 | 2026-09-03 | Davis J. E. | CEO and President | S | 10,000 | $242.72 | $2.43M | ✓ |
| 2026-08-28 | 2026-08-31 | PREVOZNIK MICHAEL E | SVP & General Counsel | S | 16,010 | $242.88 | $3.89M | ✓ |
| 2026-08-28 | 2026-08-31 | PREVOZNIK MICHAEL E | SVP & General Counsel | S | 6,237 | $243.63 | $1.52M | ✓ |
| 2026-08-28 | 2026-08-31 | PREVOZNIK MICHAEL E | SVP & General Counsel | S | 430 | $244.51 | $105.14K | ✓ |
| 2026-07-28 | 2026-07-29 | DELANEY MARK E | SVP & Chief Commercial Officer | S | 1,600 | $235.18 | $376.29K | ✓ |
| 2026-06-04 | 2026-06-08 | KUPPUSAMY KARTHIK | SVP, Clinical Solutions | S | 8,147 | $200.00 | $1.63M | ✓ |
| 2026-06-01 | 2026-06-02 | Davis J. E. | CEO and President | S | 10,000 | $194.14 | $1.94M | ✓ |
| 2026-03-05 | 2026-03-06 | Doherty Catherine T. | EVP, Regional Businesses | S | 5,558 | $206.21 | $1.15M | ✓ |
| 2026-03-05 | 2026-03-06 | PREVOZNIK MICHAEL E | SVP & General Counsel | S | 3,878 | $206.21 | $799.68K | ✓ |
| 2026-03-05 | 2026-03-06 | Plewman Patrick | SVP for Diagnostic Services | S | 2,855 | $206.21 | $588.73K | ✓ |
| 2026-03-04 | 2026-03-06 | KUPPUSAMY KARTHIK | SVP, Clinical Solutions | S | 2,628 | $204.86 | $538.37K |
| 2026-03-03 | 2026-03-04 | Doherty Catherine T. | EVP, Regional Businesses | S | 632 | $207.73 | $131.29K | ✓ |
| 2026-03-03 | 2026-03-04 | PREVOZNIK MICHAEL E | SVP & General Counsel | S | 526 | $207.73 | $109.27K | ✓ |
| 2026-03-03 | 2026-03-04 | Plewman Patrick | SVP for Diagnostic Services | S | 410 | $207.73 | $85.17K | ✓ |
| 2026-03-02 | 2026-03-04 | Davis J. E. | CEO and President | S | 10,000 | $212.52 | $2.13M | ✓ |
| 2026-02-19 | 2026-02-20 | Doherty Catherine T. | EVP, Regional Businesses | S | 1,433 | $204.83 | $293.52K | ✓ |
| 2026-02-19 | 2026-02-20 | Plewman Patrick | SVP for Diagnostic Services | S | 958 | $204.83 | $196.23K | ✓ |
| 2026-02-19 | 2026-02-20 | PREVOZNIK MICHAEL E | SVP & General Counsel | S | 1,111 | $204.83 | $227.57K | ✓ |
| 2026-02-13 | 2026-02-17 | Doherty Catherine T. | EVP, Regional Businesses | S | 3,500 | $207.08 | $724.78K | ✓ |
| 2026-02-13 | 2026-02-17 | Doherty Catherine T. | EVP, Regional Businesses | S | 1,619 | $208.21 | $337.09K | ✓ |
| 2026-02-13 | 2026-02-17 | Doherty Catherine T. | EVP, Regional Businesses | S | 351 | $209.10 | $73.39K | ✓ |
| 2026-02-13 | 2026-02-17 | Doherty Catherine T. | EVP, Regional Businesses | S | 10,573 | $205.21 | $2.17M | ✓ |
| 2026-02-13 | 2026-02-17 | Doherty Catherine T. | EVP, Regional Businesses | S | 10,122 | $206.37 | $2.09M | ✓ |
| 2026-02-10 | 2026-02-12 | Plewman Patrick | SVP for Diagnostic Services | S | 5,662 | $204.00 | $1.16M | ✓ |
| 2025-11-25 | 2025-11-28 | Davis J. E. | CEO and President | S | 41,004 | $192.27 | $7.88M | ✓ |
| 2025-11-25 | 2025-11-28 | Davis J. E. | CEO and President | S | 4,747 | $192.97 | $916.03K | ✓ |
| 2025-11-25 | 2025-11-28 | Davis J. E. | CEO and President | S | 9,342 | $191.59 | $1.79M | ✓ |
口径:Form 4/4A 公开市场买入(P)与卖出(S),申报人为董事或高管;汇总与集群为近 365 天,明细为最近 40 笔。 · 数据截至 2026-11-16 · 来源:SEC EDGAR Form 4
口径:SI 来自 FINRA(双周结算);SI% 分母 = SEC 封面总股本;借券费为 IBKR 报价(非全市场);卖空占比 = 当日卖空量/总成交量。 · 数据截至 SI 2026-10-30 · Reg SHO 2026-11-16 · 借券 2026-11-11 · 沿用上一版 · 来源:FINRA、IBKR、iBorrowDesk